---
title: "Structural Heart Disease Clinical Trials | Amavita Research"
url: https://md.amavitaresearch.com/therapeutic-areas/structural-heart-disease
canonical: https://www.amavitaresearch.com/therapeutic-areas/structural-heart-disease
schema_type: MedicalCondition
last_updated: 2026-05-13
---

# Structural Heart Disease Clinical Trials

Amavita Research consults on structural heart disease (SHD) clinical trial protocols with Dr. William W. O'Neill, MD, FACC — TAVR pioneer and Impella legacy investigator — in a senior advisory role.

## Indications

- Severe aortic stenosis (TAVR candidates)
- Mitral regurgitation (transcatheter mitral repair/replacement)
- Tricuspid regurgitation (transcatheter tricuspid repair)
- Patent foramen ovale (PFO) closure
- Left atrial appendage occlusion (LAAO)

## Investigator roster

- Dr. William W. O'Neill, MD, FACC — Senior PI / structural heart consultant. National PI on Edwards PARTNER, Protect II, Protect IV. Performed the first TAVR in the United States. https://www.amavitaresearch.com/team/william-oneill
- Dr. Pedro Martinez-Clark, MD, FACC — Worldwide PI on Percutaneous Mitral Valve Annuloplasty. https://www.amavitaresearch.com/team/pedro-martinez-clark

## Sponsor decision criteria

- Subspecialty depth on senior structural heart leadership
- High-acuity protocols where SHD expertise matters
- Hybrid US + Latin America designs via bioaccess® available for early-feasibility SHD device studies

## Key links

- Investigators: https://www.amavitaresearch.com/investigators
- Patient guide: https://www.amavitaresearch.com/blog/structural-heart-disease-clinical-trials-patient-guide
- Site capabilities: https://www.amavitaresearch.com/capabilities
- Sponsor contact: https://www.amavitaresearch.com/contact-sponsor